Free Access
Editorial
Issue
Med Sci (Paris)
Volume 32, Number 6-7, Juin–Juillet 2016
Page(s) 535 - 536
Section Éditoriaux
DOI https://doi.org/10.1051/medsci/20163206001
Published online 12 July 2016
  1. Calmette A, Guérin C, Nègre L, Boquet A. Prémunition des nouveau-nés contre la tuberculose par le vaccin BCG (1921 à 1926). Ann Inst Pasteur 1926 ; 40 : 89–133. [Google Scholar]
  2. Colditz GA, Berkey CS, Mosteller F, et al. The efficay of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995 ; 96 : 29–35. [PubMed] [Google Scholar]
  3. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994 ; 271 : 698–702. [CrossRef] [PubMed] [Google Scholar]
  4. Rodrigues LC, Pereira SM, Cunha SS. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005 ; 366 : 1290–1295. [CrossRef] [PubMed] [Google Scholar]
  5. Barreto ML, Pereira SM, Pilger D, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-age children in Brazil : second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011 ; 29 : 4875–4877. [CrossRef] [PubMed] [Google Scholar]
  6. Mascart F, Locht C. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines. Expert Rev Vaccines 2015 ; 14 : 1573–1585. [CrossRef] [PubMed] [Google Scholar]
  7. Tameris MD, Hatherill M, Landry BS, et al. MVA85 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013 ; 381 : 1021–1028. [CrossRef] [PubMed] [Google Scholar]
  8. Hinshaw HC, Feldman WH, Pfuetze KH. Treatment of tuberculosis with streptomycin: a summary of observations on one hundred cases. JAMA 1946 ; 132 : 778–782. [CrossRef] [Google Scholar]
  9. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA 1998 ; 279 : 943–948. [CrossRef] [PubMed] [Google Scholar]
  10. World Health Organization. Global tuberculosis report 2014. Geneva : WHO, WHO/HTM/TB/2014.08. [Google Scholar]
  11. Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 2016 ; 16 : e34–e46. [CrossRef] [PubMed] [Google Scholar]
  12. Willand N, Dibrié B, Carette X, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009 ; 15 : 537–544. [CrossRef] [PubMed] [Google Scholar]
  13. Bodmer T, Ströhle A.. Diagnosing pulmonary tuberculosis with the Xpert MTB/RIF test. J Vis Exp 2012 ; 62 : 3547. [PubMed] [Google Scholar]
  14. Sbarbaro JA. Skin testing in the diagnosis of tuberculosis. Semin Respir Infect 1986 ; 1 : 234. [PubMed] [Google Scholar]
  15. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Myobacterium tuberculosis infection. JAMA 2001 ; 286 : 1740–1747. [CrossRef] [PubMed] [Google Scholar]
  16. Hougardy JM, Schepers K, Place S, et al. Heparin-binding-hemagglutinin-induced IFN-α release as a diagnostic tool for latent tuberculosis. PLoS One 2007 ; 2 : e926. [CrossRef] [PubMed] [Google Scholar]
  17. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epideliological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009 ; 106 : 13980–13985. [CrossRef] [Google Scholar]
  18. Veziris N, Robert J. Résistance aux antituberculeux et impasse thérapeutique. Med Sci (Paris) 2010 ; 26 : 976–980. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Labie D. Résistances de Mycobacterium tuberculosis. Med Sci (Paris) 2007 ; 23 : 205–209. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.